Jeffrey Lazarus

He also serves as a Research Professor at the Barcelona Institute for Global Health (ISGlobal) in Spain and an adjunct professor at the Mt Sinai Medical School. His decade-long career as a health systems, HIV and viral hepatitis expert at WHO’s Regional Office for Europe was followed by three years at the Global Fund to Fight AIDS, Tuberculosis and Malaria. He is the past Vice-Chair of the EASL International Liver Foundation, Board Chair of AFEW International, and he was the first director of Health Systems Global. He is the chair of the global Healthy Livers, Healthy Lives coalition and led the first UN General Assembly MASH side-event, in 2024. Prof Lazarus is the author of more than 400 publications, including leading the landmark Global COVID-19 Consensus Statement (Nature 2022) and the steaotoic liver disease research and action priority agendas. He is a co-author of The Lancet COVID-19 Commission, the Lancet GastroHep Commission on viral hepatitis, the EASL-Lancet European Liver Commission and led The Lancet HIV series on HIV Beyond Viral Suppression. Prof Lazarus directs MASH Cities, the Global Thinktank on Steatotic Liver Disease and is co-director of the Desert Liver Conference. He has been advising governments, NGOs and WHO, as well as frequently appearing in the media to address pressing issues about the COVID-19 pandemic and liver disease. He is on the editorial board of the Journal of Hepatology and Liver International. In 2023, he received the American Liver Foundation Distinguished Scientific Achievement Award and in 2024 became a mentor for the European Association for the Study of the Liver and was named by Clarivate as a Highly Cited Researcher.